Search PubMed⌕ Search

Biomedical subjects

S R Batey

Publications and source records attributed to S R Batey.

23 records · Page 2Linked to original sources
PubMed1982

Psychoactive drug use before treatment in a child psychiatry clinic.

The patterns of prescribed and illicit psychoactive drug use by patients before admission to a child and adolescent outpatient psychiatry clinic were evaluated over a 10-year period. The charts of 328 children initially seen by the clinic in 1970, 1975, and 1980 were reviewed retrospectively. Prescribed psychoactive medications and illicit drugs used before admission to the clinic were examined according to initial year of treatment, age, sex, race, and socioeconomic status. The study population included children and adolescents between the ages of one and eighteen; 65% were males and 87% were white. Over the study period, there was little change in the total percentage of patients using prescribed psychoactive medications (range, 23% to 29%); however, the use of psychostimulants increased and the use of neuroleptic drugs decreased. Illicit drug use was reported by 3% of the patients in 1970, 10% in 1975, and 15% in 1980. Over the study period, illicit drug use involved a wider range of drugs and was reported by patients at earlier ages. Boys had higher use rates of prescribed psychoactive medications than girls; however, girls reported using more illicit drugs than boys. Two percent of the study population reported using a combination of prescribed and illicit psychoactive drugs. Over the 10-year study period, there was little change in prescribed psychoactive drug use; however, illicit drug use increased significantly. Additional studies are needed to see if similar patterns exist in other centers.

Adolescent↗
PubMed1981

Consumer education in discharge planning for continuity of care.

The need to establish continuity of care for patients in transition from the hospital; to community is essential for adequate community adjustment. The Resource Group model of discharge planning is based upon a consumer education model with emphasizes the responsibility of the individual in discharge planning. In these groups, the partial hospitalization program staff representative and the clinical pharmacist, in conjunction with inpatient clinical social workers, begin discharge planning with inpatients during the early phase of hospitalization. Increased utilization of partial hospitalization services has resulted in greater continuity of care.

Aftercare↗
PubMedDate not supplied

A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients.

This multicenter, randomized, double-masked, placebo-controlled, parallel-group study compared the antidepressant efficacy and safety of bupropion sustained-release (SR) tablets (150 mg QD or 150 mg BID) with placebo in outpatients with moderate-to-severe depression. The study consisted of a 1-week placebo phase followed by 8 weeks of active treatment with bupropion SR 150 mg/d (150 mg QD, n = 121) or 300 mg/d (150 mg BID, n = 120) or placebo (n = 121). Efficacy was measured by changes in scores on the 17-item Hamilton Rating Scale for Depression (HAM-D) and the Clinical Global Impressions for Severity of Illness (CGI-S) and Clinical Global Impressions for Improvement of Illness (CGI-I) scales. Safety was monitored by regular assessment of vital signs and adverse events as well as by pretreatment and posttreatment physical and clinical laboratory examinations. By day 56, both bupropion SR treatments were more effective in relieving the symptoms of depression than was placebo. Compared with those receiving placebo, patients in the bupropion SR 150- and 300-mg/d groups had significantly reduced symptoms by treatment day 56, as measured on the 17-item HAM-D, CGI-S, and CGI-I scales (P < 0.05). Bupropion SR was well tolerated, with no serious adverse events reported by bupropion-treated patients; 95% of all reported adverse events were of mild or moderate intensity. No clinically significant changes in vital signs, laboratory test results, or physical findings were observed. A greater mean weight loss was observed at the end of treatment in both the bupropion SR 150-mg (0.5 kg) and bupropion SR 300-mg (1.0 kg) group compared with placebo (0.2 kg). We found that bupropion SR 150 mg administered either once or twice daily was more effective than placebo in treating depression and that once-daily dosing appears to be at least as effective as twice-daily dosing. Should this prove true, depressed patients may be able to benefit from the convenience and improved tolerability associated with once-daily dosing.

Adolescent↗
PubMedDate not supplied

Bupropion sustained release (SR) for the treatment of hypoactive sexual desire disorder (HSDD) in nondepressed women.

This article describes the results of the first report of bupropion sustained release (SR) in nondepressed females with hypoactive sexual desire disorder (HSDD). Eligible females entered a 4-week, single-blind, placebo baseline phase. Subjects, all of whom did not respond to placebo, continued in a single-blind active treatment phase where they received bupropion SR for up to 8 additional weeks. We assessed HSDD by using investigator ratings of sexual desire and sexual functioning. Of the 51 evaluable subjects who entered the active treatment phase, 29% responded to treatment with bupropion SR. Bupropion SR was generally well tolerated. Pending the results of further study, bupropion SR may offer a treatment option for women with HSDD.

Adult↗